Distinguished in WT1-Related Wilms Tumor Syndromes

Dr. Bruce J. Roth

Oncology
Washington University Physicians
Washington University
5201 Mid America Plz, 
Saint Louis, MO 
Accepting New Patients

Distinguished in WT1-Related Wilms Tumor Syndromes
Washington University Physicians
Washington University
5201 Mid America Plz, 
Saint Louis, MO 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bruce Roth is an Oncologist in Saint Louis, Missouri. Dr. Roth is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Testicular Cancer, Familial Prostate Cancer, and Renal Cell Carcinoma (RCC). Dr. Roth is currently accepting new patients.

His clinical research consists of co-authoring 26 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Licenses
Internal Medicine in MO
Hospital Affiliations
Alton Memorial Hospital
Barnes-Jewish West County Hospital
Barnes Jewish Hospital
Christian Hospital Northeast
Parkland Health Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cox Health
  • EPO
  • PPO
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Alliance
  • EPO
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

WASHINGTON UNIVERSITY
5201 Mid America Plz, Saint Louis, MO 63129
Call: 800-647-2098
Other Locations
WASHINGTON UNIVERSITY
5225 Mid America Plz, Saint Louis, MO 63129
Call: 800-647-2098
WASHINGTON UNIVERSITY
1 Barnes Jewish Hospital Plz, Saint Louis, MO 63110
Call: 314-747-3000

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


8 Clinical Trials

A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
A Prospective Observational Cohort Study to Assess MiRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors
Enrollment Status: Active_not_recruiting
Publish Date: February 26, 2025
Intervention Type: Procedure, Other
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
A Phase 2 Study of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer
Enrollment Status: Completed
Publish Date: January 08, 2025
Intervention Type: Procedure, Drug
Study Drug: Ibrutinib
Study Phase: Phase 2
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
A Phase 1b Clinical Trial of Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2024
Intervention Type: Drug, Procedure
Study Drugs: Cabozantinib, Nivolumab, Abiraterone, Prednisone
Study Phase: Phase 1
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
A Pilot Trial of Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer
Enrollment Status: Completed
Publish Date: August 05, 2022
Intervention Type: Biological, Drug, Device, Procedure
Study Drugs: Nivolumab, Ipilimumab, PROSTVAC Shared Antigen Vaccine, Neoantigen DNA Vaccine
Study Phase: Phase 1
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
A Phase I/II Study of X-82, an Oral Anti-VEGFR Tyrosine Kinase Inhibitor, With Everolimus for Patients With Pancreatic Neuroendocrine Tumors
Enrollment Status: Terminated
Publish Date: July 08, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial
Enrollment Status: Withdrawn
Publish Date: August 13, 2020
Intervention Type: Procedure, Device, Drug, Biological
Study Phase: Phase 2
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Phase I Study Combining MLN8237 With Nab-Paclitaxel in Patients With Advanced Solid Malignancies
Enrollment Status: Completed
Publish Date: January 11, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

26 Total Publications

Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer (Alliance A031201 Trial).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 30, 2023
View All 26 Publications
Similar Doctors
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Joel Picus
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Joel Picus
Oncology

Washington University

4500 Forest Park Ave, 
Saint Louis, MO 
 (41.5 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joel Picus is an Oncologist in Saint Louis, Missouri. Dr. Picus is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, and Orchiectomy. Dr. Picus is currently accepting new patients.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. James J. Hsieh
Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. James J. Hsieh
Oncology
4921 Parkview Pl, Div Im Medical Oncology, Ste 7a, 7b, 7c, 
Saint Louis, MO 
 (40.9 miles away)
800-647-2098
Languages Spoken:
English
See accepted insurances

James Hsieh is an Oncologist in Saint Louis, Missouri. Dr. Hsieh is rated as an Advanced provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are Wilms Tumor, Familial Wilms Tumor 2, Renal Cell Carcinoma (RCC), and Chromophobe Renal Cell Carcinoma.

Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Mirza
Hematology Oncology | Oncology
Distinguished in WT1-Related Wilms Tumor Syndromes
Dr. Muhammad A. Mirza
Hematology Oncology | Oncology

Mercy Clinic Oncology LLC

901 Patients 1st Dr, Suite 1100, 
Washington, MO 
 (2.2 miles away)
636-390-1600
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Muhammad Mirza is a Hematologist Oncology specialist and an Oncologist in Washington, Missouri. Dr. Mirza is rated as a Distinguished provider by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. His top areas of expertise are WT1-Related Wilms Tumor Syndromes, Clear Cell Sarcoma, Adult Soft Tissue Sarcoma, and Paget Disease of the Breast. Dr. Mirza is currently accepting new patients.

VIEW MORE WT1-RELATED WILMS TUMOR SYNDROMES DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Roth's expertise for a condition
ConditionClose
    • Distinguished
    • Adult Soft Tissue Sarcoma
      Dr. Roth is
      Distinguished
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Choriocarcinoma
      Dr. Roth is
      Distinguished
      . Learn about Choriocarcinoma.
      See more Choriocarcinoma experts
    • Chromophobe Renal Cell Carcinoma
      Dr. Roth is
      Distinguished
      . Learn about Chromophobe Renal Cell Carcinoma.
      See more Chromophobe Renal Cell Carcinoma experts
    • Clear Cell Sarcoma
      Dr. Roth is
      Distinguished
      . Learn about Clear Cell Sarcoma.
      See more Clear Cell Sarcoma experts
    • Familial Prostate Cancer
      Dr. Roth is
      Distinguished
      . Learn about Familial Prostate Cancer.
      See more Familial Prostate Cancer experts
    • Familial Wilms Tumor 2
      Dr. Roth is
      Distinguished
      . Learn about Familial Wilms Tumor 2.
      See more Familial Wilms Tumor 2 experts
    View All 14 Distinguished Conditions
    • Advanced
    • Bladder Cancer
      Dr. Roth is
      Advanced
      . Learn about Bladder Cancer.
      See more Bladder Cancer experts
    • Urothelial Cancer
      Dr. Roth is
      Advanced
      . Learn about Urothelial Cancer.
      See more Urothelial Cancer experts
    • Experienced
    • Acute Myeloblastic Leukemia with Maturation
      Dr. Roth is
      Experienced
      . Learn about Acute Myeloblastic Leukemia with Maturation.
      See more Acute Myeloblastic Leukemia with Maturation experts
    • Acute Myeloblastic Leukemia without Maturation
      Dr. Roth is
      Experienced
      . Learn about Acute Myeloblastic Leukemia without Maturation.
      See more Acute Myeloblastic Leukemia without Maturation experts
    • Acute Myeloid Leukemia (AML)
      Dr. Roth is
      Experienced
      . Learn about Acute Myeloid Leukemia (AML).
      See more Acute Myeloid Leukemia (AML) experts
    • Agranulocytosis
      Dr. Roth is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Roth is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    • Breast Cancer
      Dr. Roth is
      Experienced
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    View All 40 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2025 All Rights Reserved